samedan logo
 
 
 
spacer
home > pmps > spring 2009 > fda technology transformation
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

FDA Technology Transformation

Historically, interactions between the FDA and the companies it regulates have involved the creation, printing and delivery of volumes of paper documents. These documents may have been delivered as part of an application or reviewed on-site in the course of an inspection.

Over the last few years, the FDA and industry have recognised the need for a modern, well-integrated, reliable, efficient and affordable electronic information infrastructure to support FDA administrative, regulatory and business operations. To achieve this transformational goal, the agency has embarked on a series of organisational and information technology activities. These initiatives are aimed at advancing ongoing electronic communication and interactions between the agency, the public and the companies that the FDA regulates.

As Dr Armando Oliva, FDA Deputy Director for Bioinformatics, commented: “it’s fair to say that the Agency is actively moving toward an electronic world where all regulated product information comes in electronically. I couldn’t tell when that is going to happen, but certainly there are active discussions underway to move to an ‘all electronic submission environment’ for all FDA-regulated product information, whether it be product quality, manufacturing, pre-market or post-market data” (1).


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Daniel R Matlis is the Founder and President of Axendia, Inc, a advisor to life science executives on business, technology and regulatory issues. Dan’s almost 20-year career in the life sciences industry has included projects in R&D, operations, regulatory compliance, business development and information technology. He started his professional career at a Johnson & Johnson’s Ethicon Company, where he was Technical Owner for Computer Integrated Manufacturing, Automation & IT Engineering Standards and Computer System Compliance. Prior to founding Axendia, Dan was Vice President and General Manager at Stelex (now part of GE Healthcare). He is the chief contributor and editor of Life-Science Panorama – a publication covering business, regulatory and technology issues facing industry executives.
spacer
Daniel R Matlis
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Arcis Biotechnology appointments Professor Steve Howell as Non-Executive Chairman

Daresbury, UK, 24 July 2019: Arcis Biotechnology (“Arcis”), the nucleic acid sample preparation solution provider, today announced it has appointed Professor Steve Howell as Non-Executive Chairman of its Board of Directors. Steve takes over the position from Paul Foulger, who was serving as Chairman on an interim basis on behalf of the Board.
More info >>

White Papers

Mouse Models for Evaluation of Vaccines and Therapeutics Against Staphylococcal Infections

IBT Bioservices

Introduction Staphylococcus aureus (SA) is a ubiquitous, formidable Gram-positive pathogen associated with skin and soft tissue, as well as lifethreatening systemic infections. SA is a leading cause of hospital- and community-associated infections worldwide, affecting humans and animals. The wide range of pathologies reflects the diverse abilities of this microbe to escape the innate and adaptive immune response using virulence factors. Since its first emergence in the 1960s methicillin-resistant SA (MRSA) has become endemic in hospitals and healthcare settings worldwide. In the 1990s, community associated MRSA strains (CA-MRSA) emerged, and are spreading worldwide posing a major global challenge.
More info >>

 
Industry Events

World Vaccine Congress Europe

18-21 October 2020, Barcelona, Spain

The World Vaccine Congress is an award-winning series of conferences and exhibitions that have grown to become the largest and most established vaccine meeting of its kind across the globe. Our credibility is show through the prestigious scientific advisory board that spend months of hard work creating a new and topical agenda, year on year.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement